A study published in JAMA showed that early stage bladder cancer can be missed with cystoscopy alone, but when cystoscopy is combined with NMP22® BladderChek®Test, sensitivity can be increased to 99% (Grossman et al. JAMA, January 18, 2006). The NMP22® BladderChek® Test aids in the diagnosis and monitoring of bladder cancer. The Test is CLIA waived for in-office use, economical and widely reimbursed. Results are available during the patient visit in 30 minutes using 4 drops of urine.

Visit the Bladder Cancer Diagnosis and Monitoring Center at UroToday.com We provide an educational grant to UroToday.com, a urology peer-reviewed online urology publication, to support bladder cancer education and the reporting of evidence-based bladder cancer studies, conference coverage and medical resources for urologists, urogynecologists, nurses and other medical specialists.

	More Complete. No Doubt. The only in-office test approved by the FDA as an aid in the diagnosis of bladder cancer.		The only quantitative urine immunoassay tumor marker approved as an aid in the diagnosis of bladder cancer.
	Ordering Information Inverness Medical Innovations North America, Inc. (877) 441-7440 M-F, 8:00 AM – 8:00 PM EST		Click here for more NMP22 Test Kit information.